{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Iterion+Therapeutics",
    "query": {
      "sponsor": "Iterion Therapeutics"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T00:11:10.374Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03459469",
      "title": "Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Desmoid Tumor"
      ],
      "interventions": [
        {
          "name": "Tegavivint",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Iterion Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2018-07-15",
      "completion_date": "2022-05-01",
      "has_results": false,
      "last_update_posted_date": "2023-03-01",
      "last_synced_at": "2026-09-30T00:11:10.374Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • New York, New York • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03459469"
    },
    {
      "nct_id": "NCT05797805",
      "title": "A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tegavivint",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Iterion Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2023-09-13",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-09-30T00:11:10.374Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Miami, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797805"
    },
    {
      "nct_id": "NCT07463599",
      "title": "Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Carcinoma (mCRC)",
        "Colorectal Cancer (CRC)",
        "Adenomatous Polyposis Coli (APC) Gene Mutation",
        "Catenin Beta-1 (CTNNB1) Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Tegavivint",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HonorHealth Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2026-02-17",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-30T00:11:10.374Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07463599"
    },
    {
      "nct_id": "NCT07144254",
      "title": "Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteosarcoma Recurrent",
        "Osteosarcoma in Children",
        "Relapsed Osteosarcoma",
        "Refractory Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "Tegavivint",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-01-22",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-09-30T00:11:10.374Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07144254"
    }
  ]
}